Sunovion Receives Bad News From the FDA About ADHD Drug

Sunovion Pharmaceuticals Inc. (Sunovion) announced on 8/31/18 that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the New Drug Application (NDA) for dasotraline, a novel dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of attention-deficit hyperactivity disorder (ADHD).